CORV Correvio Pharma Corp.

2.36
-0.07  -3%
Previous Close 2.43
Open 2.4
Price To Book 12.31
Market Cap 119,193,865
Shares 50,505,709
Volume 49,951
Short Ratio
Av. Daily Volume 144,491

NewsSee all news

  1. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the

  2. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S.

  3. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin Renz,

  4. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin

  5. Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV   TSX:

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Refusal to file Letter (RTF) issued August 31, 2017. NDA resubmitted with new PDUFA date April 27, 2020.
Trevyent
Pulmonary Arterial Hypertension (PAH)
PDUFA date December 24, 2019. Advisory Committee meeting likely.
Brinavess
Atrial fibrillation (AF)

Latest News

  1. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the

  2. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S.

  3. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin Renz,

  4. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin

  5. Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV   TSX:

  6. Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV   TSX: